PMID- 32323824
OWN - NLM
STAT- MEDLINE
DCOM- 20201105
LR  - 20211204
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 43
IP  - 6
DP  - 2020 Jun
TI  - TEAD2 as a novel prognostic factor for hepatocellular carcinoma.
PG  - 1785-1796
LID - 10.3892/or.2020.7578 [doi]
AB  - TEA Domain Transcription Factors (TEADs) are important in development and serve 
      essential roles in tumorigenesis; however, the role of TEAD2 expression in 
      hepatocellular carcinoma (HCC) has not been widely examined. The present study 
      was conducted to investigate the expression status of TEAD2 in HCC and to 
      evaluate whether the expression of TEAD2 is associated with the prognosis of 
      patients with HCC. mRNA expression data was retrieved for Hippo pathway genes of 
      50 normal control and 377 HCC samples from The Cancer Genome Atlas data portal. 
      Gene set enrichment, GeneNeighbors, ClassNeighbors and survival analyses were 
      then performed based on the gene expression levels. The mRNA expression of TEAD2 
      and VGLL4 was significantly higher in HCC compared with the normal control 
      samples, and the mRNA expression of TEAD2 was higher in advanced stages than in 
      early stages. Specifically, survival analysis revealed that higher mRNA 
      expression of TEAD2 was significantly associated with a less favorable overall 
      survival rate (P=0.0067) and there was a trend towards significance between 
      higher mRNA expression of VGLL4 and poor overall survival rate (P=0.051). 
      According to the gene set enrichment analysis, patients with higher mRNA 
      expression of TEAD2 and VGLL4 had strongly enhanced epithelial‑mesenchymal 
      transition and angiogenesis, which are associated with tumor progression. In 
      conclusion, increased mRNA expression of TEAD2 is associated with a poor 
      prognosis in patients with HCC. TEAD2 may serve as a prognostic factor for HCC 
      and a novel therapeutic target.
FAU - Joo, Jong Seok
AU  - Joo JS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Cho, Sang Yeon
AU  - Cho SY
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Rou, Woo Sun
AU  - Rou WS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Kim, Ju Seok
AU  - Kim JS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Kang, Sun Hyung
AU  - Kang SH
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Lee, Eaum Seok
AU  - Lee ES
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Moon, Hee Seok
AU  - Moon HS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Kim, Seok Hyun
AU  - Kim SH
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Sung, Jae Kyu
AU  - Sung JK
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Kwon, In Sun
AU  - Kwon IS
AD  - Clinical Trial Center, Chungnam National University Hospital, Jung‑gu, Daejeon 
      35015, Republic of Korea.
FAU - Eun, Hyuk Soo
AU  - Eun HS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
FAU - Lee, Byung Seok
AU  - Lee BS
AD  - Department of Internal Medicine, Chungnam National University School of Medicine, 
      Jung‑gu, Daejeon 35015, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20200406
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (TEA Domain Transcription Factors)
RN  - 0 (TEAD2 protein, human)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Apoptosis/physiology
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma, Hepatocellular/*metabolism/pathology/surgery
MH  - Case-Control Studies
MH  - Cell Movement/physiology
MH  - Cell Proliferation/physiology
MH  - Cell Transformation, Neoplastic/metabolism/pathology
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression Profiling
MH  - Humans
MH  - Liver Neoplasms/*metabolism/pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - TEA Domain Transcription Factors
MH  - Transcription Factors/genetics/*metabolism
MH  - Tumor Cells, Cultured
MH  - Young Adult
PMC - PMC7160555
OTO - NOTNLM
OT  - TEAD2
OT  - hepatocellular carcinoma
OT  - The Cancer Genome Atlas data
OT  - prognosis
OT  - survival analysis
EDAT- 2020/04/24 06:00
MHDA- 2020/11/06 06:00
PMCR- 2020/04/06
CRDT- 2020/04/24 06:00
PHST- 2019/08/21 00:00 [received]
PHST- 2020/02/14 00:00 [accepted]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/11/06 06:00 [medline]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/06 00:00 [pmc-release]
AID - or-43-06-1785 [pii]
AID - 10.3892/or.2020.7578 [doi]
PST - ppublish
SO  - Oncol Rep. 2020 Jun;43(6):1785-1796. doi: 10.3892/or.2020.7578. Epub 2020 Apr 6.